Method for building crizotinib acquired drug-resistance lung adenocarcinoma cell line
A technology of lung adenocarcinoma cells and crizotinib, which is applied in the direction of tumor/cancer cells, microbial-based methods, and detection of programmed cell death, etc. It can solve the problem of insufficient crizotinib resistance and insufficient drug screening ability And other issues
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Example 1 A method for establishing a crizotinib-acquired drug-resistant lung adenocarcinoma cell line
[0038] The method comprises the steps of:
[0039] (1) Human ROS1 gene fusion non-small cell lung cancer cell line HCC78 (hereinafter referred to as HCC78 cells) was purchased from American Type Culture Collection (ATCC). The cells were grown in RPMI 1640 medium (hereinafter referred to as complete medium) containing 10% fetal bovine serum (FBS) at 37°C, 5% CO 2 Cultured in an incubator, digested and passaged with 0.25% trypsin and ethylenediaminetetraacetic acid (0.25% Trypsin-EDTA).
[0040] (2) Take the HCC78 cells in the logarithmic growth phase for digestion and plating, and the plating density is 50%-60%. After the cells adhere to the wall, replace it with a complete medium containing 100nM crizotinib, and place it at 37 ° C, 5% CO 2 Cultured in an incubator, the complete medium containing the same concentration of crizotinib was replaced every 48-72 hours, a...
Embodiment 2
[0042] Example 2 A method for establishing a crizotinib-acquired drug-resistant lung adenocarcinoma cell line
[0043] The method comprises the steps of:
[0044] (1) Human ROS1 gene fusion non-small cell lung cancer cell line HCC78 (hereinafter referred to as HCC78 cells) was purchased from American Type Culture Collection (ATCC). The cells were grown in RPMI 1640 medium (hereinafter referred to as complete medium) containing 10% fetal bovine serum (FBS) at 37°C, 5% CO 2 Cultured in an incubator, digested and passaged with 0.25% trypsin and ethylenediaminetetraacetic acid (0.25% Trypsin-EDTA).
[0045] (2) Take the HCC78 cells in the logarithmic growth phase for digestion and plating, and the plating density is 50%-60%. After the cells adhere to the wall, replace it with a complete medium containing 80nM crizotinib, and place it at 37 ° C, 5% CO 2 Cultured in an incubator, and the complete medium containing the same concentration of crizotinib was replaced every 48 hours. Whe...
Embodiment 3
[0047] Example 3 A method for establishing a crizotinib-acquired drug-resistant lung adenocarcinoma cell line
[0048] The method comprises the steps of:
[0049] (1) Human ROS1 gene fusion non-small cell lung cancer cell line HCC78 (hereinafter referred to as HCC78 cells) was purchased from American Type Culture Collection (ATCC). The cells were grown in RPMI 1640 medium (hereinafter referred to as complete medium) containing 10% fetal bovine serum (FBS) at 37°C, 5% CO 2 Cultured in an incubator, digested and passaged with 0.25% trypsin and ethylenediaminetetraacetic acid (0.25% Trypsin-EDTA).
[0050] (2) Take the HCC78 cells in the logarithmic growth phase for digestion and plating, and the plating density is 50%-60%. After the cells adhere to the wall, replace it with a complete medium containing 120nM crizotinib, and place it at 37°C, 5% CO 2 Cultured in an incubator, the complete medium containing the same concentration of crizotinib was replaced every 48-72 hours, and...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More